%20--%3e%3c!DOCTYPE%20svg%20PUBLIC%20'-//W3C//DTD%20SVG%201.1//EN'%20'http://www.w3.org/Graphics/SVG/1.1/DTD/svg11.dtd'%20[%20%3c!ENTITY%20st0%20'fill:%23267E9A;'%3e%3c!ENTITY%20st1%20'fill:%2378C9DA;'%3e%3c!ENTITY%20st2%20'fill:%23FFFFFF;'%3e%3c!ENTITY%20st3%20'fill:%23085580;'%3e%3c!ENTITY%20st4%20'fill:%2386C34A;'%3e%3c!ENTITY%20st5%20'fill:%232FBBCC;'%3e%3c!ENTITY%20st6%20'fill:%234C6F90;'%3e%3c!ENTITY%20st7%20'fill:%23194670;'%3e%3c!ENTITY%20st8%20'fill:%2307557E;'%3e%3c!ENTITY%20st9%20'fill:%23516E89;'%3e%20]%3e%3csvg%20version='1.1'%20id='Layer_1'%20xmlns='http://www.w3.org/2000/svg'%20xmlns:xlink='http://www.w3.org/1999/xlink'%20x='0px'%20y='0px'%20viewBox='0%200%2032%2032'%20style='enable-background:new%200%200%2032%2032;'%20xml:space='preserve'%3e%3cg%3e%3cg%3e%3crect%20x='10.3'%20y='14'%20style='&st5;'%20width='5'%20height='4.4'/%3e%3crect%20x='10.3'%20y='12'%20style='&st5;'%20width='11.4'%20height='1'/%3e%3crect%20x='16.4'%20y='14'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='15.8'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='17.5'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='16.4'%20y='19.3'%20style='&st5;'%20width='5.3'%20height='0.9'/%3e%3crect%20x='10.3'%20y='19.3'%20style='&st5;'%20width='5'%20height='0.9'/%3e%3cg%3e%3cpath%20style='&st5;'%20d='M22.6,22.3H9.4c-0.6,0-1.2-0.5-1.2-1.2v-10c0-0.6,0.5-1.2,1.2-1.2h13.1c0.6,0,1.2,0.5,1.2,1.2v10%20C23.7,21.7,23.2,22.3,22.6,22.3z%20M9.4,10.8c-0.1,0-0.3,0.1-0.3,0.3v10c0,0.1,0.1,0.3,0.3,0.3h13.1c0.1,0,0.3-0.1,0.3-0.3v-10%20c0-0.1-0.1-0.3-0.3-0.3H9.4z'/%3e%3c/g%3e%3c/g%3e%3cpath%20style='&st5;'%20d='M16,30.2C8.2,30.2,1.8,23.8,1.8,16S8.2,1.8,16,1.8S30.2,8.2,30.2,16S23.8,30.2,16,30.2z%20M16,2.8%20C8.7,2.8,2.8,8.7,2.8,16S8.7,29.2,16,29.2S29.2,23.3,29.2,16S23.3,2.8,16,2.8z'/%3e%3c/g%3e%3c/svg%3e)
Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Retina News
10/30/2026
BreakingCataractDealsIndiaRetinaSurgical
Appasamy Acquires Ruck and its Qube Pro Dual-Function Platform
India’s Appasamy Associates, a portfolio company of Warburg Pincus, reported Oct. 22 that it had acquired German company Ruck, manufacturer of ophthalmic surgical products for both the front and ba...
10/30/2026
BreakingCornealDry EyeGlaucomaIOLLaserPremiumPresbyopiaRetinaRevenue
Q3-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Glaukos, Novartis, Lumibird, and Lenz
Bausch + Lomb reported Oct. 28 that its Q3-2026 revenue totaled $1.4 billion, a 7 percent increase (+8 percent cc) from $1.3 billion in Q3-2025. Ophthalmic pharmaceuticals segment revenue was $367 ...
10/30/2026
BreakingClinical TrialGene TherapyRegulationRetina
US FDA Gives Green Light to Trial of Opus’ Gene Therapy for RDH12-LCA
Opus Genetics announced on Oct. 21 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of OPGx-RDH12, a gene therapy ca...
10/30/2026
BreakingDiagnosticLaserRetina
Volk Launches ClearField Pro Lens for Retinal Exams, Laser Treatment
Volk Optical announced Oct. 7 the launch of ClearField Pro, a new ophthalmic lens designed for retinal examination and laser indirect ophthalmoscopy. The lens’ advanced coating provides up to 77 pe...
10/30/2026
BreakingCell TherapyEuropeRegulationRetina
EMA Grants Orphan Drug Status to BlueRock’s IRD Cell Therapy Candidate
Bayer subsidiary BlueRock Therapeutics announced Sept. 30 that its investigational cell therapy, lemiretprocel (OpCT-001), had received orphan drug designation from the European Medicines Agency. T...
10/23/2026
BreakingDealsRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
10/23/2026
BreakingCataractIOLPharmaPremiumRetinaRevenueSurgical
Q3-2026 Ophthalmic Revenue Roundup for Roche and J&J Vision
Swiss company Roche reported Oct. 22 that Q3-2026 Vabysmo sales were CHF 1.1 billion ($1.4 billion, converted for Sept. 20, 2026) a 13 percent increase over CHF 996 million in Q3-2025. US Vabysmo s...
10/23/2026
BreakingClinical TrialIndustryPharmaRetina
EyePoint to Slash Workforce, End Pivotal Wet AMD Trials After Second Miss for Duravyu
EyePoint announced Oct. 19 that it would cut its workforce by 53 percent and end the Phase III trials for Duravyu in wet age-related macular degeneration (AMD) early after the LUCIA study failed to...
10/23/2026
BreakingPharmaRegulationRetina
Belite Files for Approval of Oral Stargardt Candidate in Singapore, UK, Switzerland
Belite Bio announced Oct. 14 that it had filed for marketing approval for its oral Stargardt treatment candidate, tinlarebant, in three countries—Singapore, the UK, and Switzerland—under those nati...
10/21/2026
DealsGene TherapyNewsletterRetina
Gene Therapy Reclaims Top Spot in Ophthalmic Fundraising
Ophthalmic gene therapy fundraising has reached nearly $1.3 billion in 2026, propelled by major investments in Beacon Therapeutics, Regenxbio, and MeiraGTx. Beacon closed a Series C round in Januar...
10/21/2026
DealsIOLNewsletterRetina
Saunders Departs Bausch + Lomb, as Chairman Appio Takes Over
Bausch + Lomb announced Oct. 12 that CEO Brent Saunders would leave the company immediately, with chairman Thomas Appio taking over as interim CEO. Appio also is CEO of Bausch Health. Saunders had ...
10/21/2026
AcquisitionsDealsNewsletterRetina
Alcon Acquires Neurotech and its MacTel Treatment Encelto for $550 Million
Alcon announced Oct. 20 that it had acquired Neurotech Pharmaceuticals, maker of Encelto for macular telangiectasia Type 2 (MacTel), for $550 million. Alcon said that it might be required to make a...
10/21/2026
GlaucomaNewsletterRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, October 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
10/21/2026
FundingGene TherapyNewsletterRetinaThyroid Eye Disease
City Therapeutics Leads Latest Fundraising with $230 Million IPO
City Therapeutics led recent ophthalmic fundraising efforts with a $230 million upsized initial public offering to advance its candidates for GA and Stargardt. Financing announced in the past four ...
10/21/2026
DealsNewsletterPharmaRetina
Glaukos Licenses Tri-specific Retinal Candidate from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics exclusive rights to RO-104, a novel tri-specific biologic candidate targeting wet age-related macular degeneration, diabetic...
9/4/2026
BreakingCataractEuropeGlaucomaIndiaIndustryMeetingNewsletterRefractiveRetina
2026-2027 Ophthalmic Meetings Calendar
Market Scope regularly updates its list of ophthalmic meetings to keep the information current. Please contact us at matthewdouty@market-scope.com if we do not have your meeting listed. Thank you.
10/21/2026
AICataractDiagnosticDigitalDry EyeEmergingIOLMyopiaNewsletterOculomicsRetinaSurgical
Emerging Companies Pursuing Ophthalmic Indications, October 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
10/21/2026
Cell TherapyClinical TrialCornealGene TherapyNewsletterRetinaThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, October 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
10/21/2026
BiosimilarsCell TherapyChinaClinical TrialCornealDealsDiagnosticFundingGene TherapyGlaucomaIndustryMyopiaNewsletterOptometryRegulationRetinaSurgical
October 2026 Ophthalmic News Briefs
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen, the first FDA-approved ready-to-use indocyanine green (ICG) injection in the US. Sagent said conventio...
10/16/2026
BiosimilarsBreakingEuropeRegulationRetina
Alvotech, Advanz Submit Marketing Application to EMA for High-Dose Aflibercept Biosimilar
Alvotech and partner Advanz Pharma announced Oct. 14 that they had submitted a marketing authorization application to the European Medicines Agency (EMA) for AVT29, a proposed biosimilar to Eylea (...
10/16/2026
BreakingClinical TrialPharmaRetina
Merck Sees Mixed Results at One Year in Pivotal Trial of Remigromig in DME
Merck presented one-year results from remigromig’s pivotal Phase IIb/III BRUNELLO trial at the 2026 meeting of the American Academy of Ophthalmology (AAO), held Oct. 10-12 in New Orleans, Louisiana...
10/16/2026
BreakingPharmaRegulationRetinaUveitis
US FDA Accepts BLA for Genentech’s Vamikibart in UME; Decision Expected by July 2027
Genentech, a member of the Roche group, reported Oct. 10 that the US FDA had accepted the biologics license application (BLA) for vamikibart, an intravitreal IL-6 inhibitor candidate for uveitic ma...
10/9/2026
BreakingDealsRetina
Glaukos Licenses Tri-specific Retinal Candidate RO-104 from RevOpsis
Glaukos announced Oct. 8 that it had licensed from RevOpsis Therapeutics the exclusive rights to develop and commercialize RO-104, a novel tri-specific biologic candidate targeting wet age-related ...
10/9/2026
BreakingDiagnosticRetina
Sagent Launches Zyogreen Ready-to-Use Indocyanine Green Dye for Injection in the US
Sagent Pharmaceuticals, of Schaumburg, Illinois, announced Sept. 22 the US launch of Zyogreen (indocyanine green injection). Sagent said Zyogreen is the first and only FDA-approved ready-to-use ind...
10/9/2026
BreakingGene TherapyRetina
Nobel Prize for Medicine Goes to Team First to Publish Optogenetics Findings
Three scientists who helped develop optogenetics received the 2026 Nobel Prize in Physiology or Medicine on Oct. 5. They are Karl Deisseroth, MD, PhD, of the Howard Hughes Medical Institute in Mary...
10/9/2026
BreakingGene TherapyRegulationRetina
Japanese Regulators Accept NDA for Nanoscope’s Optogenetic Gene Therapy Candidate, Grant Priority Review
Nanoscope Therapeutics announced Oct. 1 that regulators in Japan had accepted the company’s new drug application for Mogenry, an optogenetic gene therapy candidate targeting inherited retinal dystr...
10/9/2026
BreakingClinical TrialPharmaRegulationRetina
US FDA Gives Green Light to Trial of Surrozen’s DME Candidate
Surrozen announced on Oct. 2 that the US FDA had signed off on its investigational new drug application, allowing the company to proceed with a clinical trial of SZN-8141, a bifunctional Wnt agonis...
10/2/2026
BreakingGene TherapyRegulationRetina
Ocugen Gains Provisional Approval in Bahamas to Treat RP Patients with OCU400
Ocugen announced Sept. 25 that OCU400, its subretinal modifier gene therapy candidate targeting retinitis pigmentosa (RP), had been granted provisional approval and priority designation by regulato...
10/2/2026
BreakingCataractIndustryRefractiveRetinaSurgical
Sightpath Medical Adds Retinal Equipment to Mobile Offering
Sightpath Medical reported Sept. 22 that it now delivers retinal equipment for ophthalmic surgery. The company’s mobile services for retina specialists include delivery of a vitrectomy platform in ...
10/2/2026
BreakingCell TherapyChinaClinical TrialRetina
iRegene’s RP Cell Therapy Candidate Gets Green Light for Clinical Trials in China, US
China’s iRegene Therapeutics announced Sept. 29 that its cell therapy candidate targeting retinitis pigmentosa (RP) gained authorization from regulators to enter clinical trials in both China and t...
9/25/2026
BreakingEuropeRegulationRetina
Roche Gains EU Approval for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced Sept. 21 that the European Commission had granted marketing authorization for Susvimo (ranibizumab injection) 100 mg/mL for the treatment of wet age-related macular ...
9/25/2026
BreakingDiagnosticFundusOCTRetina
Zeiss Introduces Alta Duo 300, a Fully Automated OCT Combination Retinal Imager
Zeiss Medical Technology reported Sept. 17 that it had introduced the Alta Duo 300 combination retinal imager. The device will be available in select markets later in 2026. The German company said ...
9/25/2026
BreakingDiagnosticFundusOCTRetina
Combination OCT-Fundus Camera Headlines Product Launches from Nidek
Japan’s Nidek announced Sept. 3 the launch of three new ophthalmic diagnostic offerings. The RSD-1 Duo, a combined OCT and fundus camera system, and the AFC-1 fundus camera increase efficiency acro...
9/25/2026
BreakingFundingRetinaStudy
€1 Million Champalimaud Vision Award in 2026 Goes to Botond Roska and José-Alain Sahel
The winners of the 2026 António Champalimaud Vision Award are researchers Botond Roska, MD, PhD, of Switzerland, and José-Alain Sahel, MD, of France and the US, for their pioneering optogenetic the...
9/25/2026
BreakingIndustryLaserRetina
Norlase Establishes Direct Commercial Presence in the United Kingdom
Norlase announced on Sept. 8 that it had expanded its footprint in Europe with a direct commercial presence in the United Kingdom. The Danish company, with US offices in Redwood City, California, a...
9/22/2026
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 5.4 Percent Decrease in Q2-2026 Procedure Volume
US ophthalmologists reported that ophthalmic procedures decreased 5.4 percent in Q2-2026 compared with the same quarter in 2025, according to Market Scope’s latest survey. Year-over-year performanc...
9/22/2026
Cell TherapyGene TherapyNewsletterRetina
New IRD Therapies Could Shake Up Nonexudative Retinal Pharma Market
Complement inhibitors reaped more than three-quarters of manufacturers’ revenue in the nonexudative retinal pharmaceuticals market in 2025, but candidates for inherited retinal diseases (IRD) are g...
9/22/2026
NewsletterPresbyopiaRetinaThyroid Eye Disease
PDUFA Dates for Ophthalmic Drug Candidates, September 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
9/22/2026
Clinical TrialNewsletterPharmaRegulationRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
9/22/2026
EuropeNewsletterPharmaRetinaSingle-Use
Oxford Eye Hospital Initiative Cuts IVT Injection Waste and Costs
Britain’s Oxford Eye Hospital reported Aug. 24 that an initiative there to change the way intravitreal (IVT) injections are administered has eliminated tons of associated single-use product waste a...
9/22/2026
CornealDealsDry EyeFundingNewsletterPharmaPresbyopiaRefractiveRetina
Ingenia Leads Latest Fundraising with $42.3 Million Initial Public Offering
Ingenia Therapeutics led recent ophthalmic fundraising efforts, which totaled $57.3 million in the past four weeks.
9/22/2026
Cell TherapyClinical TrialGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, September 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
9/22/2026
AIDiagnosticEmergingLow VisionNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, September 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
9/22/2026
AIChinaDealsDry EyeEuropeGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRetinaSurgical
September 2026 Ophthalmic News Briefs
UK-based Rayner reported Sept. 7 the launch of its Galaxy Hydrophobic spiral IOL. The lens will be available commercially in the EU in Q4-2026. The original Galaxy spiral IOL, a full range of visio...
9/18/2026
BreakingGene TherapyRegulationRetina
US FDA Accepts BLA for Nanoscope’s Optogenetic Gene Therapy Candidate in RP
Nanoscope Therapeutics announced Sept. 9 that the US FDA had accepted for review its biologics license application (BLA) for Mogenry, an optogenetic gene therapy candidate designed to restore visio...
9/18/2026
BreakingPharmaRegulationRetina
Surrozen Submits IND Application for Dual-Acting SZN-8141 in DME
Surrozen announced Sept. 8 that it had submitted an investigational new drug (IND) application to the US FDA to launch a clinical trial of SZN-8141, a bifunctional Wnt agonist and vascular endothel...
9/18/2026
BreakingPharmaRegulationRetina
Belite Bio Submits NDA in Japan for Oral Tinlarebant in Stargardt
Belite Bio announced Sept. 8 that it had submitted a new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant, to Japan’s Ministry of Health, Labour, and Welfare. Tinlareb...
9/18/2026
BreakingFundingRetina
Foundation Fighting Blindness Renames Venture Arm as Gund Vision Fund
The Foundation Fighting Blindness, of Columbia, Maryland, reported Sept. 10 that it had renamed its venture philanthropy arm the Gund Vision Fund. The fund was formerly called the Retinal Degenerat...
9/11/2026
BreakingEuropeRetinaSingle-Use
Oxford Eye Hospital Initiative Cuts IVT Injection Waste and Costs
Britain’s Oxford Eye Hospital reported Aug. 24 that an initiative there to change the way intravitreal (IVT) injections are administered has eliminated tons of associated single-use product waste a...
9/11/2026
EuropeGlaucomaRetina
UK Government Outlines Measures to Reduce Ophthalmology Waiting Times
The UK government on Aug. 25 outlined initiatives intended to reduce ophthalmology waiting times, address regional disparities, and move more eye care into community and digital settings. Gillian J...
9/11/2026
BreakingRetina
British Company Exonate Rebrands as Foventa Therapeutics
British company Exonate announced Sept. 1 that it had changed its name to Foventa Therapeutics. The company said its new name and motto “Simply Sharper” take inspiration from the fovea, the center ...
9/4/2026
BreakingDealsRetina
Kiora Licenses Retinal Candidate to Chong Kun Dang for South Korea
Kiora Pharmaceuticals announced Aug. 10 that it had granted Chong Kun Dang (CKD) Pharmaceutical Corp. development and commercialization rights in South Korea to KIO-301 for the treatment of degener...
9/4/2026
BreakingIndustryLow VisionRetina
Samsara Vision Promotes Jason Herod to President and Chief Executive Officer
Samsara Vision, of Far Hills, New Jersey, announced Sept. 1 that Jason Herod had been promoted to president and chief executive officer. Herod joined Samsara in 2021 and most recently served as chi...
8/28/2026
BreakingPharmaRegulationRetina
Japan Grants Orphan Status to Alkeus’ Oral Gildeuretinol for Stargardt
Alkeus Pharmaceuticals announced Aug. 24 that Japan’s Ministry of Health, Labour, and Welfare had granted orphan drug status to gildeuretinol, its oral therapy candidate for Stargardt disease. In J...
8/20/2026
NewsletterRetina
Biosimilars, Longer-Acting Treatments Depress Exudative Retinal Pharma Revenue
Total manufacturers’ revenue from pharmaceuticals for exudative retinal diseases are on course to decline for the second year in a row—a first since the introduction of anti-VEGF therapy in 2004. M...
8/21/2026
BreakingCataractChinaFLACSGlaucomaLaserPresbyopiaRefractiveRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for STAAR, Lensar, Iridex, and Lenz
STAAR Surgical, of Lake Forest, California, reported Aug. 12 that its Q2-2026 net sales were $93.5 million, a 111 percent increase over $44.3 million in Q2-2025. China sales in Q2-2026 were $52.3 m...
8/20/2026
MeetingNewsletterRetinaSurgical
ASRS Meeting Shines Light on Ingenuity of Retina Surgeons Around the Globe
The 2026 annual meeting of the American Society of Retina Specialists (ASRS), held in mid-July at the Palais des Congrès in Montreal, Quebec, opened with a deep dive into surgery. The first day off...
8/21/2026
BiosimilarsBreakingDiagnosticIOLPharmaRetinaRevenueSurgical
Quarterly Revenue Roundup for Carl Zeiss Meditec and Santen
German company Carl Zeiss Meditec reported Aug. 6 that its ophthalmic device revenue for the three months ended June 2026 (the third quarter of its fiscal 2025/2026 year) was €437.6 million ($499.7...
8/21/2026
BreakingClinical TrialRetina
EyePoint’s Duravyu Misses Primary Visual Acuity Endpoint in Phase III Wet AMD Trial
EyePoint Pharmaceuticals reported Aug. 17 that Duravyu (vorolanib intravitreal insert) missed its primary visual acuity endpoint in topline results from the Phase III LUGANO trial in wet age-relate...
8/20/2026
AcquisitionsDealsNewsletterRetina
Tarsus Enters Retina Sector with Two Acquisitions that Could Top $1 Billion
Tarsus Pharmaceuticals, maker of Xdemvy drops for Demodex blepharitis, has ventured into the retina sector recently with two acquisitions that could end up topping $1 billion. Tarsus said its deals...
8/20/2026
NewsletterPresbyopiaRegulationRetina
PDUFA Dates for Ophthalmic Drug Candidates, August 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) and Biosimilar User Fee Act (BsUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
8/20/2026
NewsletterRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
8/20/2026
BiosimilarsNewsletterRetina
India’s Biocon Launches Aflibercept Biosimilar Yesafili in the US
India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...
8/20/2026
MeetingNewsletterRetina
ASRS Session Builds Anticipation for GA Candidate Aiming to Preserve Vision
The 2026 annual meeting of the American Society of Retina Specialists offered encouraging news for patients suffering from geographic atrophy (GA). Margaret Chang, MD, MS, of the Retina Consultants...
8/20/2026
MeetingNewsletterPharmaRetina
Retinal Treatment Durability Takes Center Stage at ASRS Meeting
Treatment durability was a recurring theme in sessions throughout the 2026 annual meeting of the American Society of Retina Specialists. Day 2 of the meeting began with a session titled, “Beyond An...
8/20/2026
CataractGlaucomaLaserMeetingNewsletterRetina
Smaller Ophthalmic Surgical Lasers Demonstrate Flexibility and Effectiveness
Miniaturization has emerged in recent years as a key innovation in ophthalmic surgical laser technology, and smaller laser systems were on display at the 2026 annual meeting of the American Society...
8/20/2026
EuropeLow VisionNewsletterProsthesisRetina
Science Corp. Launches Prima Retinal Implant for GA in Europe
Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...
8/20/2026
CataractChinaClinical TrialCornealDealsDiagnosticDry EyeFundingGene TherapyGlaucomaIOLNewsletterPharmaRetinaSurgical
Tarsus Leads Latest Fundraising with $125 Million Private Placement
Tarsus Pharmaceuticals led recent ophthalmic fundraising efforts with a $125 million private placement for clinical development and commercial activities. Financing announced in the past four weeks...
8/20/2026
CataractDealsDry EyeGlaucomaLaserNewsletterRetina
IPG Photonics to Acquire Lumibird Medical for $342.3 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
8/20/2026
IndiaNewsletterRetinaSurgical
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...
8/20/2026
Clinical TrialGene TherapyGlaucomaMyopiaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, August 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
8/20/2026
CataractGlaucomaNewsletterRegulationRetinaSurgical
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...
8/20/2026
Clinical TrialEmergingGene TherapyNewsletterOcular CancerRetina
Emerging Companies Pursuing Ophthalmic Indications, August 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
8/20/2026
AllergyCataractChinaDealsDiagnosticDry EyeEuropeFundusGene TherapyGlaucomaIOLIndustryLow VisionMyopiaNewsletterPharmaPresbyopiaRefractiveRegulationRetinaSurgical
August 2026 Ophthalmic News Briefs
Bausch + Lomb announced July 16 that it had launched the EyeGility Inserter preloaded IOL delivery system in the US. The inserter is available now with the enVista Aspire intermediate-optimized mon...
8/14/2026
BreakingPharmaRegulationRetina
US FDA Accepts NDA for Belite’s Oral Stargardt Candidate, Grants Priority Review
Belite Bio announced Aug. 11 that the US FDA had accepted its new drug application (NDA) for its oral Stargardt treatment candidate, tinlarebant. The agency granted priority review, and set a Presc...
8/14/2026
BreakingCataractDry EyeGlaucomaIOLOcular CancerPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Alcon, Tarsus, Immunocore, Harrow, Sight Sciences, and ANI
Alcon reported Aug. 10 that its Q2-2026 net sales totaled $2.8 billion, an 8 percent increase over $2.6 billion in Q2-2025. Alcon also announced that it had discontinued work on the PowerVision Flu...
8/14/2026
BreakingDealsRetina
Oculis Buys Out Global Rights to Privosegtor from Accure
Swiss company Oculis announced Aug. 10 that it would obtain worldwide development and commercialization rights to privosegtor as part of an asset purchase agreement with Spain’s Accure Therapeutics...
8/14/2026
BreakingChinaClinical TrialRetina
US FDA Gives Green Light to Trial of Ractigen’s saRNA Candidate in PVR
China’s Ractigen Therapeutics reported on July 31 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I clinical trial of ...
8/14/2026
BreakingGene TherapyRegulationRetina
US FDA Grants RMAT Status to Ocugen’s Gene Therapy Candidate for GA
Ocugen announced July 29 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to OCU410, the company’s subretinal gene therapy candidate for geographic atrophy (GA)...
8/7/2026
BreakingDealsDry EyePharmaRetina
Tarsus to Acquire Alkeus Pharmaceuticals in Deal Worth up to $800 Million
Tarsus Pharmaceuticals, maker of Xdemvy, announced Aug. 6 that it would acquire Alkeus Pharmaceuticals in a cash-and-stock deal worth up to $800 million. Under the deal, Tarsus will pay $450 milli...
8/7/2026
BiosimilarsBreakingCataractIOLLaserPharmaRetinaRevenueSurgicalThyroid Eye Disease
Q2-2026 Ophthalmic Revenue Roundup for Regeneron, Amgen, Hoya, Astellas, Novartis, Lumibird, Ocular Therapeutix, and Xbrane
Regeneron, of Tarrytown, New York, reported July 30 that its Q2-2026 US revenue for Eylea HD and Eylea 2 mg was $1.0 billion, a 12 percent decrease from $1.15 billion in Q2-2025. Eylea HD accounted...
8/7/2026
BiosimilarsBreakingRetina
Biocon Launches Eylea Biosimilar Yesafili in the US
India’s Biocon Limited announced on Aug. 3 the commercial launch of Yesafili (aflibercept-jbvf), a biosimilar to Eylea 2 mg, in the US. Yesafili was among a flurry of Eylea biosimilars approved by ...
8/7/2026
BreakingIndiaIndustryRetinaSurgical
Aravind, Alcon Open Centre of Excellence for Vitreoretinal Surgery Training in India
Aravind Eye Care System and Alcon reported July 24 that they had launched the Aravind Alcon Global Centre of Excellence for Vitreoretinal Surgery Training in Coimbatore, India. The move marks the s...
8/7/2026
BreakingEuropePharmaRegulationRetina
Roche Receives Positive CHMP Opinion for Susvimo Sustained-Release Wet AMD Treatment
Swiss drugmaker Roche announced July 24 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had recommended marketing authorization in the European Union for ...
7/31/2026
BreakingPharmaRegulationRetina
US FDA Approves Outlook’s Lytenava (Bevacizumab) for Wet AMD
Outlook Therapeutics announced July 24 that it had gained US FDA approval for Lytenava (bevacizumab-vikg) to treat wet age-related macular degeneration (AMD). The news comes after years of regulato...
7/31/2026
BreakingCataractCornealDry EyeGene TherapyGlaucomaIOLMIGSPharmaRetinaRevenueSurgical
Q2-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Roche, and Glaukos
Bausch + Lomb reported July 29 that its Q2-2026 revenue was $1.4 billion, a 9 percent increase over $1.3 billion in Q2-2025, driven by a 64 percent increase in implantables, including a 175 percent...
7/31/2026
BreakingEuropeLow VisionRetina
Science Corp. Launches Prima Retinal Implant in Europe
Science Corporation reported July 22 that it had launched its Prima retinal implant in Europe for patients with geographic atrophy (GA) caused by age-related macular degeneration (AMD). The company...
7/31/2026
BreakingGene TherapyRegulationRetina
Atsena’s Gene Therapy Candidates for XLRS, LCA1 Gain EMA Orphan Designation
Atsena Therapeutics announced July 23 that the European Medicines Agency (EMA) had granted orphan designation to its two clinical-stage gene therapy candidates: ATSN-101 for Leber congenital amauro...
7/24/2026
BreakingCataractGlaucomaRegulationRetinaSurgical
CMS Proposes Cuts to Physician Fees for 2027; Simple Cataract Surgery Would Pay $462 or $444
The Centers for Medicare and Medicaid Services (CMS) on July 14 published its proposed Physician Fee Schedule (PFS) for 2027. Similar to the 2026 schedule, one of two conversion factors will be use...
7/24/2026
BreakingCataractDealsDry EyeGlaucomaLaserRetina
IPG Photonics to Acquire Lumibird Medical for €300 Million
IPG Photonics has entered into a binding offer to acquire Lumibird Medical for €300 million (US $342.3 million), both companies announced July 16. A contingent earnout consideration of up to an add...
7/24/2026
BreakingGene TherapyRetina
Atsena Will Advance ATSN-401 Gene Therapy Candidate for Stargardt
Atsena Therapeutics announced July 9 that it would advance ATSN-401, a gene therapy candidate for Stargardt disease. Stargardt is an inherited neurodegenerative disease that leads to macular degene...
7/24/2026
BreakingDealsGene TherapyRetina
Ocugen Secures Deal with Roots Pharmaceutical for OCU400 in MENA Region
Ocugen announced July 13 that it had signed a binding term sheet for a license agreement with Kuwait’s Roots Pharmaceutical for exclusive rights to OCU400, Ocugen’s subretinal modifier gene therapy...
7/24/2026
BreakingIndustryPharmaRetina
NovaBridge Biosciences Appoints Srishti Gupta, MD, as Chief Executive Officer
NovaBridge Biosciences announced June 29 that it had appointed Srishti Gupta, MD, as chief executive officer and a member of the company’s board of directors. The company said that Xi-Yong (Sean) F...
7/24/2026
BreakingIndustryPharmaRetina
Exonate Appoints Olav Hellebø as Chief Executive Officer
British company Exonate announced June 30 that it had appointed Olav Hellebø as chief executive officer. Exonate is developing EXN407, an eye drop candidate entering Phase IIb study for diabetic ey...
7/21/2026
BiosimilarsCornealDiagnosticDry EyeFundingGene TherapyNewsletterRetina
Ollin Leads Latest Fundraising with $330 Million in Series B Financing
Ollin Biosciences led recent ophthalmic fundraising efforts with $330 million in a Series B round to advance its candidates for retinal and thyroid eye disease. Financing announced in the past four...
7/21/2026
BiosimilarsEuropeNewsletterRegulationRetina
Harrow Relaunches Samsung Bioepis’ Biosimilar Byooviz in the US
Harrow announced July 1 that it had relaunched Byooviz, a Lucentis biosimilar, in the US. The Nashville, Tennessee, company secured US rights to Byooviz (ranibizumab-nuna) and another ophthalmic bi...
7/21/2026
CataractDiagnosticDry EyeEmergingNewsletterPharmaRetina
Emerging Companies Pursuing Ophthalmic Indications, July 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
7/21/2026
CataractClinical TrialDry EyeGene TherapyNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, July 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
7/21/2026
AICataractChinaDealsDiagnosticDigitalFundusGlaucomaIOLIndustryNewsletterPharmaRefractiveRegulationRetinaSurgical
July 2026 Ophthalmic News Briefs
Johnson & Johnson reported June 15 that it would invest more than $1 billion in its Jacksonville, Florida, operations to scale US-based manufacturing, packaging, and distribution for its Acuvue con...
7/17/2026
AllergyBreakingCataractPharmaRegulationRetina
US FDA Recalls 2.5 Million Bottles of Prednisolone Acetate Eye Drops
The US FDA has issued a Class II recall of more than 2.5 million bottles of prednisolone acetate 1% eye drops manufactured by Lupin Limited, citing the possibility of foreign particulate contaminat...
7/17/2026
BreakingClinical TrialGlaucomaRetina
Bausch + Lomb Drops Glaucoma Neuroprotection Program after Phase II Failure
Bausch + Lomb announced July 10 that it would discontinue development of a neuroprotective eye drop candidate for glaucoma, citing Phase II results in which BL1107, a prodrug of brimonidine tartrat...
7/17/2026
BreakingDealsDry EyeRetinaSurgical
Tarsus Acquires iRenix, Developer of Pre-procedure Ocular Antiseptic Candidate
Tarsus Pharmaceuticals announced July 8 that it had acquired iRenix Medical, of Palo Alto, California, developer of IRX-101, an investigational ocular antiseptic. Tarsus said it would pay approxima...
7/10/2026
BiosimilarsBreakingRetina
Harrow Relaunches Lucentis Biosimilar Byooviz in the US
Harrow announced July 1 that it had relaunched Byooviz (ranibizumab-nuna), a Lucentis biosimilar, in the US. The Nashville, Tennessee, company secured US rights to Byooviz and another ophthalmic bi...
7/2/2026
BreakingDealsIndustryRetina
LambdaVision Collaborates with Vast, Creator of Planned Commercial Space Station
LambdaVision reported June 24 that it had signed a memorandum of understanding with Vast related to future research and manufacturing activities for LambdaVision’s artificial retina aboard Vast’s p...
7/2/2026
BreakingCataractDiagnosticGlaucomaMicroscopesRetinaSurgical
BVI Opens Experience Hub for Ophthalmic Training, Collaboration
BVI Medical, of Waltham, Massachusetts, announced June 15 that it had opened a new BVI Experience Hub within its offices in Sant Cugat, Spain. The hub is designed to support ophthalmic training and...
6/26/2026
BreakingDry EyeRetina
Scope Health Adds Vision Support and Eye Comfort Eyetamins to its Optase Product Line
Scope Health, of New York, announced June 17 that it had added Eyetamins Vision Support and Eye Comfort versions to its Optase line of eyelid hygiene and ocular lubricant products. The Eye Comfort ...
6/19/2026
BreakingPharmaRegulationRetina
Belite Bio Completes Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced June 12 that it had completed its rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califo...
6/18/2026
MeetingNewsletterRetina
2026 ARVO Meeting Draws Big Attendance, Rare Snowstorm
The 2026 meeting of the Association for Research in Vision and Ophthalmology (ARVO) drew 10,996 attendees, the second largest attendance to date, coming in just under the 2024 total of 11,631. The ...
6/19/2026
BreakingGlaucomaIndustryPharmaRetina
Tavo Biotherapeutics Appoints Federico Grossi, MD, PhD, as CMO
Tavo Biotherapeutics, of Laguna Beach, California, announced June 2 that it had appointed Federico Grossi, MD, PhD, as chief medical officer (CMO). Grossi most recently was CMO of Unity Biotechnolo...
6/18/2026
CataractChinaDry EyeGlaucomaNewsletterRetina
Regulatory Changes, Off-Brand Competition Reshape Ophthalmic Market in China
Continued change is shifting the dynamics of the ophthalmic market in China, boosting revenue growth in some sectors while slowing it in others. Changes are both regulatory and competitive. Regulat...
6/18/2026
CataractEarningsGlaucomaNewsletterRefractiveRetinaRevenueSurgical
Ophthalmic Company Revenue Increases 3.7 Percent in First Quarter of 2026
Ophthalmic manufacturer revenue in Q1-2026 totaled $11.4 billion. Revenue increased 3.7 percent from the same quarter in 2025 and decreased 2.9 percent from Q4-2025. The total includes Market Scope...
6/18/2026
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 4.7 Percent Decrease in Q1-2026 Procedure Volume
US ophthalmologists reported that ophthalmic procedures decreased 4.7 percent in Q1-2026 compared with the same quarter in 2025, according to Market Scope’s latest survey. Year-over-year performanc...
6/18/2026
Clinical TrialNewsletterRetina
Oculis Scraps DME Eye Drop Program after Missing Phase III Endpoints
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
6/18/2026
DiagnosticIOLNewsletterRegulationRetina
Select US FDA Approvals and Clearances in May 2026
The US FDA’s ophthalmic device division granted clearance to two devices using the 510(k) pathway in May 2026, according to the agency’s database. Heidelberg received clearance for its updated Spec...
6/18/2026
NewsletterPresbyopiaRegulationRetinaThyroid Eye Disease
PDUFA Dates for Ophthalmic Drug Candidates, June 2026
The US FDA has scheduled the following Prescription Drug User Fee Act (PDUFA) target action dates for ophthalmic drug, drug/device, and biologic candidates.
6/18/2026
FundingGlaucomaNewsletterPharmaRetinaSurgicalThyroid Eye Disease
Ethyreal Bio Leads Latest Fundraising with $101 Million in Series A
Ethyreal Bio led recent ophthalmic fundraising efforts with $101 million in a Series A financing to advance its subcutaneous candidate for thyroid eye disease. Financing announced in the past four ...
6/18/2026
Clinical TrialGene TherapyMeetingNewsletterRegulationRetina
2026 ARVO Keynote Speaker Says ‘Age of RNA’ Has Arrived
Thomas Cech, PhD, declared the 21st century “the age of RNA” during his opening keynote address at the 2026 ARVO meeting. Sally Temple, PhD, used the closing keynote to talk about the future of ste...
6/18/2026
NewsletterRetina
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US for patients with age-related macular degeneration (AMD) at risk of progression. The supplements co...
6/18/2026
Clinical TrialCornealDry EyeGene TherapyGlaucomaNewsletterRetina
Clinical Trial Updates for Ophthalmic Candidates, June 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
6/18/2026
NewsletterPharmaRegulationRetina
Outlook Therapeutics Resubmits BLA for Lytenava After Winning FDA Appeal
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
6/18/2026
DiagnosticDigitalDry EyeEmergingGene TherapyMicroscopesNewsletterRetinaSurgicalThyroid Eye Disease
Emerging Companies Pursuing Ophthalmic Indications, June 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
6/18/2026
AIAllergyAmblyopiaCataractClinical TrialDealsDiagnosticIOLIndustryLaserMicroscopesMyopiaNewsletterOptometryPharmaRegulationRetinaSingle-UseSurgical
June 2026 Ophthalmic News Briefs
UK-based Rayner announced June 1 the launch of Ophteis Cohesive, a new OVD formulated with a high molecular weight to optimize space creation and ease of removal. Ophteis Cohesive is packaged at 1....
6/12/2026
BiosimilarsBreakingEuropeRetina
Formycon’s Aflibercept Biosimilar in Prefilled Syringes Now Available in EU
Germany’s Formycon announced May 19 that its aflibercept (Eylea) biosimilar, known in various territories as Ahzantive and Baiama, was now available in the European Union. It is being introduced in...
6/12/2026
BiosimilarsBreakingEuropeRetina
Samsung Bioepis Launches Aflibercept Biosimilar Branded Opuviz in EU
Korea’s Samsung Bioepis announced May 29 that it had launched Opuviz, a biosimiliar referencing Eylea (aflibercept), across Europe. The biosimilar is also available in Korea and Canada as Aflivu. H...
6/12/2026
BiosimilarsBreakingRegulationRetina
Lupin Gains US FDA Approval for Ranibizumab Biosimilar Branded Ranluspec
India’s Lupin Limited announced June 4 that the US FDA had approved Ranluspec (ranibizumab-hkdz) as an interchangeable biosimilar referencing Lucentis. Lupin said Ranluspec was the only interchange...
6/12/2026
BiosimilarsBreakingRegulationRetina
Alvotech Resubmits BLA to US FDA for Aflibercept Biosimilar
Alvotech, of Reykjavik, Iceland, reported June 4 that it had resubmitted its biologics license application (BLA) to the US FDA for AVT06, a biosimilar to Eylea (aflibercept). Alvotech said it had a...
6/12/2026
BreakingDiagnosticOCTRetina
Optos Names Alexandre Montague as CEO
UK-based Optos announced June 9 that it had appointed Alexandre Montague as chief executive officer, effective immediately. Optos, a subsidiary of Japan’s Nikon, pioneered ultra-widefield retinal i...
6/5/2026
BreakingClinical TrialPharmaRetina
Oculis Scraps DME Eye Drop Program after Phase III Failure
Swiss company Oculis reported May 29 that it would not pursue US FDA approval for OCS-01, its dexamethasone eye drop candidate targeting diabetic macular edema (DME), after the primary endpoint of ...
6/5/2026
BreakingPharmaRegulationRetina
Outlook Therapeutics Resubmits BLA for Lytenava After Winning Appeal with FDA
Outlook Therapeutics reported June 1 that it had resubmitted its biologics license application (BLA) to the US FDA for Lytenava, its ophthalmic formulation of bevacizumab for the treatment of wet a...
6/5/2026
BreakingDealsLaserRetina
Zeiss, M2care Invest in Maculaser, Developer of Temperature-Controlled Retinal Laser Therapy
Finland-based Maculaser Oy has received a new investment from Zeiss Ventures, the corporate venture capital arm of Germany’s Zeiss Group, and M2care, a European health tech venture studio, as Macul...
5/29/2026
BreakingGlaucomaRefractiveRetina
Q1-2026 Ophthalmic Revenue Roundup for Apellis, Immunocore, STAAR, and Iridex
Apellis Pharmaceuticals, of Waltham, Massachusetts, reported May 7 in its quarterly financial report for Q1-2026 that its net product revenue for Syfovre was $150.7 million, a 15.4 percent increase...
5/29/2026
BreakingRegulationRetina
US FDA Signs Off on Special Protocol Assessment for Oculis’ Optic Neuritis Trial
Swiss company Oculis announced May 7 that the US FDA had agreed to a special protocol assessment regarding PIONEER-1, a Phase III clinical trial evaluating Privosegtor for the treatment of optic ne...
5/22/2026
BreakingRetina
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the US
Bausch + Lomb reported May 19 that it had launched its PreserVision AREDS3 eye vitamins in the US. The supplements add a unique B-vitamin complex to the AREDS2 nutrients recommended by the National...
5/22/2026
BreakingGene TherapyRetina
Portuguese Study of Luxturna Shows Functional Benefits, Structural Decline
Luxturna (voretigene neparvovec) has demonstrated in clinical trials and real-world studies that it improves light sensitivity and functional vision, with a favorable safety profile. A new prospect...
5/15/2026
BreakingDealsDiagnosticOculomicsRetina
NeuroVision Acquires Durin Life Sciences to Advance Neurological Diagnostics
NeuroVision, the developer of Afina retinal imaging technology to detect neurodegenerative disease, announced May 12 that it had acquired Durin Life Sciences, of Stratford, New Jersey. No financial...
5/14/2026
AcquisitionsDealsGlaucomaNewsletterRetina
Bayer to Acquire Perfuse in Deal Worth Up to $2.45 Billion
German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...
5/14/2026
BiosimilarsCornealLaserNewsletterRegulationRetina
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...
5/14/2026
FundingGene TherapyNewsletterPharmaRetinaThyroid Eye Disease
Viridian Leads Latest Fundraising with $250 Million in Public Offerings
Viridian Therapeutics led recent ophthalmic fundraising efforts with $250 million in public offerings of convertible notes and Series B stock to advance its TED candidates. Financing announced in t...
5/14/2026
EuropeNewsletterRetinaSurgical
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...
5/14/2026
DiagnosticDigitalEmergingMyopiaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, May 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
5/14/2026
CataractClinical TrialCornealGene TherapyIOLNewsletterRetinaSurgicalThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, May 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
5/14/2026
FundingGene TherapyNewsletterRetina
Inventors of Luxturna Win $3 Million Breakthrough Prize
Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...
5/14/2026
NewsletterRetinaStudy
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...
5/14/2026
BiosimilarsCataractCornealDealsDry EyeEuropeIndustryMyopiaNewsletterPresbyopiaRegulationRetinaSurgical
May 2026 Ophthalmic News Briefs
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
5/8/2026
BreakingDealsGlaucomaPharmaRetina
Bayer to Acquire Perfuse Therapeutics in Deal Worth Up to $2.45 Billion
German drugmaker Bayer announced May 6 that it would acquire Perfuse Therapeutics in a deal worth up to $2.45 billion. Perfuse, of South San Francisco, California, is advancing PER-001 for glaucoma...
5/8/2026
BiosimilarsBreakingCataractIOLRetinaRevenueSurgicalThyroid Eye Disease
Quarterly Ophthalmic Revenue Roundup for Alcon, Amgen, Hoya, Ocular Therapeutix, and Xbrane
Alcon reported May 6 that its Q1-2026 net sales were $2.69 billion, a 10 percent increase (+6 percent cc) over $2.45 billion in Q1-2025. Surgical net sales totaled $1.46 billion, consisting of $438...
5/8/2026
BreakingDeviceEuropeRetinaSurgical
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb announced May 7 the European launch of the Bi-Blade+ dual-port vitrectomy cutter on the Stellaris Elite dual-function cataract and vitrectomy system. The Bi-Blade+ now offers 25 thous...
5/8/2026
BiosimilarsBreakingRegulationRetina
Xbrane Resubmits BLA to US FDA for Lucentis Biosimilar
Sweden’s Xbrane Biopharma announced April 30 that it had resubmitted the biologics license application (BLA) for its Lucentis (ranibizumab) biosimilar to the US FDA. A complete response letter from...
5/8/2026
BreakingDealsRetina
Novelty Nobility Taps AGC Biologics to Help Advance Bispecific Retinal Candidate
South Korea’s Novelty Nobility announced May 4 that it had expanded its manufacturing agreement with AGC Biologics to advance retinal disease candidate NN4101 through process development and GMP ma...
5/8/2026
BreakingDealsEuropeRetina
Kubota Vision, Laboratoires Kôl Team Up on Compassionate Use of Stargardt Candidate
Kubota Vision and Laboratoires Kôl announced May 4 that they had signed a supply and licensing agreement to bring emixustat hydrochloride, an oral treatment candidate for Stargardt disease, to pati...
5/8/2026
BreakingClinical TrialRegulationRetina
US FDA Accepts Opus’ LCA5 Gene Therapy Candidate into New Rare Disease Program
Opus Genetics announced May 4 that the US FDA had accepted OPGx-LCA5, a gene therapy candidate targeting Leber congenital amaurosis type 5, into the new Rare Disease Evidence Principles (RDEP) prog...
5/1/2026
BreakingCataractEquipmentEuropeRegulationRetinaSurgical
BVI Announces Full CE Marking for its Virtuoso Platforms
BVI Medical reported April 20 that itsVirtuoso cataract-only and dual-function cataract-vitrectomy platforms had gained CE marking under the new European Union Medical Device Regulation (MDR). The ...
5/1/2026
BreakingCataractCornealGlaucomaIOLLaserPharmaRetinaRevenueSurgical
Q1-2026 Ophthalmic Revenue Roundup for Bausch + Lomb, Regeneron, Glaukos, Astellas, Novartis, and Lumibird
Bausch + Lomb reported April 29 that its Q1-2026 revenue was $1.24 billion, a 9 percent increase (+6 percent cc) over $1.14 billion in Q1-2025. Surgical segment revenue was $228 million, a 7 percen...
5/1/2026
BreakingRetinaStudy
Scientists Deliver Healthy Mitochondria to Sick Cells, Including Eye Cells
Swiss scientists reported April 15 that they had developed a technology that can deliver healthy mitochondria directly to cells most affected by disease. They called their approach a major step tow...
5/1/2026
BreakingDealsPharmaRetina
Ligand to Acquire Xoma, Including its Vabysmo Royalties, for $739 Million
Jupiter, Florida-based Ligand Pharmaceuticals and Xoma Royalty Corporation, of Emeryville, California, announced April 27 that Ligand would acquire Xoma for $39 per share of common stock in cash, f...
5/1/2026
BreakingPharmaRegulationRetina
Belite Bio Initiates Rolling NDA Submission for Oral Tinlarebant in Stargardt
Belite Bio announced April 21 that it had initiated a rolling new drug application (NDA) submission to the US FDA for oral tinlarebant for the treatment of Stargardt disease. The San Diego, Califor...
5/1/2026
BreakingEuropeGene TherapyRegulationRetina
EMA Grants PRIME Designation to Ray Therapeutics’ Optogenetic RP Candidate
Ray Therapeutics announced April 29 that the European Medicines Agency had granted Priority Medicines (PRIME) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)...
4/24/2026
BreakingFundingGene TherapyRetina
Inventors of Luxturna Win $3 Million Breakthrough Prize
Penn Medicine’s Jean Bennett, MD, PhD, and Albert Maguire, MD, along with Katherine High, MD, of Children’s Hospital of Philadelphia (CHOP), have been awarded a prestigious Breakthrough Prize in Li...
4/24/2026
BreakingPharmaRetinaRevenue
Roche Reports Q1-2026 Vabysmo Sales of $1.3 Billion
Swiss company Roche reported April 23 that Vabysmo sales in Q1-2026 were CHF 1.024 billion ($1.3 billion, calculated for March 31, 2026), up 13 percent in constant currency from CHF 1.018 billion i...
4/24/2026
BiosimilarsBreakingCornealGlaucomaLaserRegulationRetina
US CMS Issues J-Codes and Q-Codes for Four Ophthalmic Products in Q1-2026
The US Centers for Medicare and Medicaid Services (CMS) issued J-codes in Q1-2026 for Harrow’s Iopidine and Glaukos’ Epioxa and Epioxa HD. In addition, the CMS issued Q-codes for Zydec’s interchang...
4/24/2026
BreakingDealsDiagnosticGlaucomaOCTRetina
Revenio Group to Acquire Visionix in $341 Million Deal
Finland’s Revenio Group, parent of ophthalmic diagnostic company iCare, announced April 13 that it would acquire France-based Visionix in a deal worth €290 million ($341 million). Revenio said that...
4/24/2026
BreakingPharmaRegulationRetina
US FDA Approves Vabysmo for Extended Dosing Beyond 6 Months in RVO
Genentech announced April 9 that the US FDA had approved the extension of dosing intervals for Vabysmo (faricimab-svoa) beyond six months for patients with macular edema due to retinal vein occlusi...
4/21/2026
AcquisitionsDealsNewsletterRetina
Cencora Expands Reach in Retina Care with Acquisition of EyeSouth Partners
Cencora’s agreement to purchase the retinal business of EyeSouth Partners for $1.1 billion is the company’s second major acquisition in an aggressive campaign to become a major, vertically integrat...
4/21/2026
AcquisitionsDealsNewsletterRetina
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth
Biogen reported March 31 that it had agreed to acquire Apellis Pharmaceuticals, maker of Syfovre, for about $5.6 billion in cash to expand its portfolio of rare-disease medicines. Under the deal, e...
4/21/2026
CataractDiagnosticIOLNewsletterRetina
Select US FDA Approvals and Clearances in March 2026
The US FDA’s ophthalmic device division granted clearance to three devices using the 510(k) pathway in March 2026, according to the agency’s database. Oculus received clearance for its Pentacam Cor...
4/21/2026
DeviceNewsletterRetinaSurgical
Incremental Improvements are the Trend in Vitrectomy Systems
New retinal surgical device offerings from manufacturers feature innovative fluidics systems and stiffer small-gauge instruments. Manufacturers hope the improvements they bring to vitrectomy surger...
4/21/2026
FundusGene TherapyGlaucomaNewsletterPharmaRetina
Life Bio Leads Latest Fundraising with $80 Million in Series D Round
Life Biosciences led recent ophthalmic fundraising efforts with $80 million in Series D funding to advance its cell rejuvenation therapy pipeline. Financing announced in the past four weeks totaled...
4/21/2026
Cell TherapyClinical TrialCornealGene TherapyNewsletterRetinaThyroid Eye Disease
Clinical Trial Updates for Ophthalmic Candidates, April 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
4/21/2026
ChinaClinical TrialEmergingGlaucomaIOLNewsletterProsthesisRetina
Emerging Companies Pursuing Ophthalmic Indications, April 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
4/21/2026
DealsGene TherapyNewsletterRetina
Meira GTx Pays J&J $25 Million to Buy Back Gene Therapy Candidate for XLRP
MeiraGTx announced April 16 that it would reacquire all interests in bota-vec, a gene therapy candidate it developed targeting X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson. MeiraGTx...
4/21/2026
BiosimilarsCataractCell TherapyChinaClinical TrialCornealDiagnosticDigitalDry EyeIOLIndiaIndustryMicroscopesNewsletterPharmaRegulationRetina
April 2026 Ophthalmic News Briefs
Swiss ophthalmic diagnostics company Haag-Streit announced March 31 the global launch of its Metis 3D Digital Heads-Up Module (Metis HU). The system was launched in the US in October 2025. Metis HU...
4/17/2026
BreakingDealsGene TherapyRetina
MeiraGTx Pays J&J $25 Million to Buy Back Gene Therapy Candidate for XLRP
MeiraGTx announced April 16 that it would reacquire all interests in bota-vec, a gene therapy candidate it developed targeting X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson. MeiraGTx...
4/17/2026
BreakingDeviceRetinaSurgical
Bausch + Lomb Gains US FDA Clearance for Bi-Blade+ Cutter and Adaptive Fluidics Update
Bausch + Lomb announced April 8 that the US FDA had granted 510(k) clearance for the Bi-Blade+ dual-port cutter and Adaptive Fluidics update for the Stellaris Elite dual-function cataract and vitre...
4/17/2026
BreakingPharmaRegulationRetina
US FDA Grants Orphan Drug Status to Drug Farm’s ROSAH Candidate
Drug Farm, of Shanghai, China, announced March 26 that the US FDA had granted orphan drug status to DF-003, an oral alpha kinase 1 (ALPK1) inhibitor targeting the rare genetic disease ROSAH syndrom...
4/17/2026
BreakingEmergingPharmaRegulationRetina
US FDA Grants Orphan Drug Status to SignaBlok’s ROP Candidate
SignaBlok, of Shrewsbury, Massachusetts, announced March 26 that the US FDA had granted orphan drug status to its TREM-1 peptide inhibitor targeting retinopathy of prematurity (ROP). Orphan drug de...
4/17/2026
BreakingGene TherapyRegulationRetina
US FDA Grants RMAT Status to Ray Therapeutics’ Optogenetic RP Candidate
Ray Therapeutics announced April 1 that the US FDA had granted regenerative medicine advanced therapy (RMAT) designation to RTx-015, its optogenetic therapy candidate for retinitis pigmentosa (RP)....
4/10/2026
BreakingPharmaRegulationRetina
US FDA Approves Eylea HD for Extended Dosing Intervals up to 5 Months
Regeneron announced April 2 that the US FDA had approved the extension of dosing intervals for Eylea HD (aflibercept 8 mg) up to every 20 weeks for patients with wet age-related macular degeneratio...
4/10/2026
BreakingClinical TrialDeviceRegulationRetina
US FDA Gives Green Light to Trial of i-Lumen’s Bioelectric Stimulation Device for Dry AMD
i-Lumen Scientific announced March 31 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a pivotal trial of its bioelectri...
4/3/2026
BreakingDealsPharmaRetina
Biogen to Acquire Apellis for $5.6 Billion with Eye Toward Growth
Biogen reported March 31 that it had agreed to acquire Apellis Pharmaceuticals, maker of Syfovre, for about $5.6 billion in cash to expand its portfolio of rare-disease medicines. Under the deal, ...
4/3/2026
BiosimilarsBreakingIndustryRetina
Biocon Appoints Shreehas Tambe as CEO, Managing Director
India’s Biocon Limited announced March 27 that it had appointed Shreehas Tambe as its chief executive officer and managing director, effective April 1. The company said Tambe joined Biocon nearly t...
3/27/2026
BreakingDealsRetina
Cencora to Acquire EyeSouth Partners’ Retina Business for $1.1 Billion
Cencora announced March 23 that it had agreed to acquire the retina business of EyeSouth Partners for $1.1 billion. The move follows Cencora’s $4.6 billion deal in January 2025 to buy Retina Consul...
3/27/2026
BreakingGlaucomaLaserPresbyopiaRetinaRevenue
2025 Ophthalmic Revenue Roundup for Iridex and Lenz
Iridex, of Mountain View, California, reported March 26 that its 2025 revenue was $52.7 million, an 8 percent increase over $48.7 million in 2024. Cyclo G6 product revenue was $13.8 million, a 9 pe...
3/27/2026
BreakingCataractDiagnosticFundusGlaucomaLaserRetinaSurgical
Zeiss Expands Clinical Ophthalmic and Optometric Device Portfolio in Canada
Carl Zeiss Meditec announced March 24 the addition of several advanced diagnostic, visualization, and therapeutic devices to its ophthalmic and optometric portfolio in Canada. Zeiss said its Clarus...
3/27/2026
BreakingChinaClinical TrialRetina
Innovent Reports Positive Phase III Results for Extended-Dosing Retinal Candidate
China’s Innovent Biologics reported March 23 that IBI302 (efdamrofusp alfa), its extended-dosing retinal candidate, met its primary visual acuity endpoint at week 52 in the Phase III STAR study. IB...
3/27/2026
BreakingCell TherapyRegulationRetina
US FDA Grants Orphan Drug Status to Sumitomo’s RP Cell Therapy Candidate
Japan’s Sumitomo Pharma announced March 23 that the US FDA had granted orphan drug status to DSP-3077, its allogeneic retinal sheets in Phase I/II study for retinitis pigmentosa. Orphan drug design...
3/24/2026
GlaucomaIOLNewsletterRefractiveRetina
Ophthalmologists Report 2.1 Percent Decrease in Q4-2025 Procedure Volume
------ Refractive: -17.3 IOL: +5.0 Glaucoma: +4.2 Retina: -5.7 ----- US ophthalmologists reported that ophthalmic procedures decreased 2.1 percent in Q4-2025 compared with the same quarter in 2024,...
3/24/2026
NewsletterPharmaRegulationRetina
US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data
Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...
3/24/2026
CataractEuropeNewsletterRetinaSurgical
Oertli Launches OS 4 Up Dual-Function Cataract-Vitrectomy System in Europe
Switzerland-based Oertli announced Feb. 23 that its OS 4 Up dual-function cataract/vitrectomy machine is now available in all CE-certified markets. Features include adaptive energy delivery with Ph...
3/24/2026
DeviceDiagnosticFundingGene TherapyGlaucomaNewsletterOculomicsRetinaSurgical
Science Corp. Leads Latest Fundraising with $230 Million in Series C
Science Corporation led recent ophthalmic fundraising efforts with $230 million in a Series C round to support its Prima implant for dry age-related macular degeneration. Financing announced in the...
3/24/2026
Clinical TrialCornealGene TherapyGlaucomaMyopiaNewsletterPharmaRetina
Clinical Trial Updates for Ophthalmic Candidates, March 2026
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
3/24/2026
AllergyDry EyeEmergingGene TherapyGlaucomaNewsletterRetina
Emerging Companies Pursuing Ophthalmic Indications, March 2026
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
3/24/2026
DeviceNewsletterRetina
Weekly Poll of MDs and ODs, March 2026
3/24/2026
BiosimilarsCataractClinical TrialCornealDealsDiagnosticEuropeFundingGlaucomaIOLIndustryNewsletterPresbyopiaRefractiveRegulationRetinaStudySurgical
March 2026 Ophthalmic News Briefs
STAAR Surgical announced Feb. 17 that the US FDA had approved an expanded age indication for Evo and Evo+ implantable Collamer lenses (ICLs), extending their use from patients 21 to 45 years old to...
3/20/2026
BiosimilarsBreakingEuropeRetina
Formycon Settlement Clears Way for Eylea Biosimilar in Europe, Other Markets
German companies Formycon and Klinge Biopharma reported March 19 that they had reached a settlement and license agreement with Regeneron and Bayer that clears the way for commercialization of Ahzan...
3/13/2026
BreakingPharmaRegulationRetina
US FDA Rejects Chiesi’s Idebenone for LHON, Asks for More Clinical Data
Chiesi reported March 5 that the US FDA had issued a complete response letter rejecting the company’s new drug application (NDA) for oral idebenone to treat Leber hereditary optic neuropathy (LHON)...
3/6/2026
BiosimilarsBreakingCataractEuropeIOLPharmaRetinaRevenueSurgicalUveitis
Ophthalmic Quarterly and 2025 Revenue for Carl Zeiss Meditec, Harrow, RxSight, ANI, and Xbrane
Million Carl Zeiss Meditec reported Feb. 12 that ophthalmology revenue for the last three months of 2025, the first quarter of its fiscal year 2025/2026, totaled €356.9 million ($419.2 million, con...
3/6/2026
BreakingCell TherapyClinical TrialRegulationRetina
US FDA Gives Green Light to Phase I/II Trial of Sanaregen’s Retinal Cell Therapy Candidate
Sanaregen Vision Therapeutics reported March 3 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of its retin...
3/6/2026
BiosimilarsBreakingEuropeRegulationRetina
Sandoz Reports EU Approval for Ranibizumab Biosimilar Branded Ranluspec
Swiss drugmaker Sandoz announced Feb. 23 that the European Commission had granted marketing authorization for Ranluspec, a ranibizumab biosimilar developed by India’s Lupin Limited. Sandoz holds ex...
3/6/2026
BreakingCell TherapyFundingGene TherapyRetina
Cirrus Expands to Singapore, Unveils GA Cell Therapy Candidate
Cirrus Therapeutics reported March 3 that it had established an R&D site in Singapore, expanding its presence in the Asia-Pacific region. The Cambridge, Massachusetts, company also unveiled a secon...
3/6/2026
BreakingCell TherapyDealsRetina
Axol Bioscience Acquires Ophthalmology Business from Newcells Biotech
UK-based Axol Bioscience, a provider of induced pluripotent stem cell (iPSC) technologies for drug discovery and research, reported Feb. 18 that it had acquired the ophthalmology business of Newcel...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.